Filing Flows › Allogene Therapeutics (ALLO) › Q2 2026
Allogene Therapeutics (ALLO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
Allogene Therapeutics (ALLO) reported revenue of $4.6M for the second quarter 2026 (Q2 2026).
Allogene Therapeutics, Q2 2026: revenue $4.6M, net loss $42.7M, operating cash flow −$32.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.6M | — | — |
| Operating profit | −$46.9M | — | — |
| Net earnings | −$42.7M | — | — |
| Operating cash flow | −$32.0M | — | — |
What changed
Revenue was $4.6M in Q2 2026.
Operating costs exceeded revenue by $46.9M, an operating margin of -1011.2%. The quarter ended with a net loss of $42.7M.
Operating cash flow was −$32.0M. Non-cash charges added back $2.6M of depreciation and amortization and $12.4M of share-based compensation. Working capital and other items used $4.4M. Capital expenditures of $150K exceeded it, leaving free cash flow of −$32.1M.
Questions
What was Allogene Therapeutics' revenue in the second quarter 2026?
Allogene Therapeutics (ALLO) reported revenue of $4.6M for the second quarter 2026 (Q2 2026).